China · Delayed Price · Currency is CNY Sirio Pharma Statistics
Total Valuation
Sirio Pharma has a market cap or net worth of CNY 5.33 billion. The enterprise value is 6.38 billion.
| Market Cap | 5.33B |
| Enterprise Value | 6.38B |
Important Dates
The next confirmed earnings date is Saturday, August 29, 2026.
| Earnings Date | Aug 29, 2026 |
| Ex-Dividend Date | Jun 5, 2026 |
Share Statistics
Sirio Pharma has 307.02 million shares outstanding. The number of shares has increased by 0.77% in one year.
| Current Share Class | 307.02M |
| Shares Outstanding | 307.02M |
| Shares Change (YoY) | +0.77% |
| Shares Change (QoQ) | -0.43% |
| Owned by Insiders (%) | 20.70% |
| Owned by Institutions (%) | 16.76% |
| Float | 112.06M |
Valuation Ratios
The trailing PE ratio is 45.01 and the forward PE ratio is 14.28.
| PE Ratio | 45.01 |
| Forward PE | 14.28 |
| PS Ratio | 1.24 |
| PB Ratio | 1.80 |
| P/TBV Ratio | 2.55 |
| P/FCF Ratio | 137.14 |
| P/OCF Ratio | 10.83 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 24.44, with an EV/FCF ratio of 164.23.
| EV / Earnings | 54.15 |
| EV / Sales | 1.48 |
| EV / EBITDA | 24.44 |
| EV / EBIT | 29.11 |
| EV / FCF | 164.23 |
Financial Position
The company has a current ratio of 1.85, with a Debt / Equity ratio of 0.61.
| Current Ratio | 1.85 |
| Quick Ratio | 1.36 |
| Debt / Equity | 0.61 |
| Debt / EBITDA | 6.93 |
| Debt / FCF | 46.59 |
| Interest Coverage | 2.25 |
Financial Efficiency
Return on equity (ROE) is 0.21% and return on invested capital (ROIC) is 5.51%.
| Return on Equity (ROE) | 0.21% |
| Return on Assets (ROA) | 2.42% |
| Return on Invested Capital (ROIC) | 5.51% |
| Return on Capital Employed (ROCE) | 4.73% |
| Weighted Average Cost of Capital (WACC) | 5.24% |
| Revenue Per Employee | 1.55M |
| Profits Per Employee | 42,434 |
| Employee Count | 2,776 |
| Asset Turnover | 0.76 |
| Inventory Turnover | 6.11 |
Taxes
| Income Tax | -24.81M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.12% in the last 52 weeks. The beta is 0.24, so Sirio Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.24 |
| 52-Week Price Change | -25.12% |
| 50-Day Moving Average | 17.30 |
| 200-Day Moving Average | 21.49 |
| Relative Strength Index (RSI) | 56.42 |
| Average Volume (20 Days) | 1,526,535 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sirio Pharma had revenue of CNY 4.31 billion and earned 117.80 million in profits. Earnings per share was 0.39.
| Revenue | 4.31B |
| Gross Profit | 1.23B |
| Operating Income | 219.09M |
| Pretax Income | -18.97M |
| Net Income | 117.80M |
| EBITDA | n/a |
| EBIT | 219.09M |
| Earnings Per Share (EPS) | 0.39 |
Balance Sheet
The company has 766.87 million in cash and 1.81 billion in debt, with a net cash position of -1.04 billion or -3.40 per share.
| Cash & Cash Equivalents | 766.87M |
| Total Debt | 1.81B |
| Net Cash | -1.04B |
| Net Cash Per Share | -3.40 |
| Equity (Book Value) | 2.97B |
| Book Value Per Share | 9.70 |
| Working Capital | 921.58M |
Cash Flow
In the last 12 months, operating cash flow was 491.66 million and capital expenditures -452.82 million, giving a free cash flow of 38.84 million.
| Operating Cash Flow | 491.66M |
| Capital Expenditures | -452.82M |
| Depreciation & Amortization | 212.71M |
| Net Borrowing | 148.97M |
| Free Cash Flow | 38.84M |
| FCF Per Share | 0.13 |
Margins
Gross margin is 28.50%, with operating and profit margins of 5.08% and 2.73%.
| Gross Margin | 28.50% |
| Operating Margin | 5.08% |
| Pretax Margin | -0.44% |
| Profit Margin | 2.73% |
| EBITDA Margin | n/a |
| EBIT Margin | 5.08% |
| FCF Margin | 0.90% |
Dividends & Yields
This stock pays an annual dividend of 0.13, which amounts to a dividend yield of 0.79%.
| Dividend Per Share | 0.13 |
| Dividend Yield | 0.79% |
| Dividend Growth (YoY) | -80.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 154.60% |
| Buyback Yield | -0.77% |
| Shareholder Yield | 0.01% |
| Earnings Yield | 2.21% |
| FCF Yield | 0.73% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Sirio Pharma is 25.00, which is 43.35% higher than the current price. The consensus rating is "Buy".
| Price Target | 25.00 |
| Price Target Difference | 43.35% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 10.30% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on May 27, 2025. It was a forward split with a ratio of 1.3.
| Last Split Date | May 27, 2025 |
| Split Type | Forward |
| Split Ratio | 1.3 |
Scores
Sirio Pharma has an Altman Z-Score of 3.02 and a Piotroski F-Score of 4.
| Altman Z-Score | 3.02 |
| Piotroski F-Score | 4 |